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the 2 major predictors of death. After reclassification of patients into High Risk and Low 
Risk categories according to the presence of well established deleterious factors for 
CABG (LVEF< 35%, age >75y, poor run off, renal faiture, and obstructive lung disease) 
we estimated survival by KMA. 
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Conclusions: coronary stenting can be an alternative to CABG in low risk patients, with 
satisfactory 3 years outcome. In high risk patients for CABG this technique is feasible but 
the long term prognosis remains poor. 
1126-16 Primary Stenting With Abciximab in Acute Myocardial 
Infarction Complicated by Cardiogenic Shock (the 
ADMIRAL Trial) 
Gilles MontalQscot. Paul Barragan, Olivier Wittenberg, Simon Elhadad, Thierry Lef(bvra, 
Christophe Loubeyre, Antoine Lafont, Michel Zupan, Franck Paganelli, Philippe Pinton, 
Piti~ Salp{~tdbre Hospital, Paris, France. 
Patients with acute myocardial infarction (AMI) in oardiogeeic shock are at high-risk of 
mortality. In the randomized double blind ADMIRAL study, 300 patients undergoing pri- 
mary stenting for AMI were allocated to either abciximab or placebo. Twenty five patients 
(8.3 percent) amongst them presented a cardiogenic shock (CS) within the first 24 hours: 
7.3 percent in the abciximab group and 9.3 percent in the placebo group (P=0.55). The 
shock patients had more frequent dyslipidemia (P=0.01), prior myocardial infarction 
(P=0.02), prior PTCA (P=O.03) and diabetes (P=0.03) than non-shock patients. They 
were also more frequently male (P=O.05). The mortality rate was significantly higher in 
CS patients than in non-cardiogenic shock patients at 30 days (16 percent vs. 4 percent, 
respectively, P=O.O08) and at 6 months (16 percent vs. 4.4 percent, P=O.01). The rate of 
TIMI grade 2 or 3 flow was lower in CS patients compared to the others, on admission 
(8.3 percent vs. 19.3 percent, P=0.34) and at 24 hours (83.3 percent vs. 94.8 percent, 
P=0.23). The 24-hour re-occlusion rate was also higher (16.7 percent vs. 6.5 percent, 
respectively P=0.34). In CS patients, the rate of TIMI grade 2 or 3 flow was slightly higher 
with abciximab compared to placebo (14.3 percent vs. 0.0 percent, P=0.34) as well as at 
24 hours (100.0 percent va. 83.3 percent, P=0.34); the 24-hour re-occlusion rate was 
lower with abciximab (0.0 percent vs. 33.3 percent, P=0.21). At both 30 days and 6 
months, in CS patients, the primary endpoint including (death, myocardial infarction and 
urgent target vessel revascularization) tended to be lower with abciximab (9.1 percent 
versus 28.6 percent, P=0.23), Death was reduced by 57 percent with abciximab (9.1 per- 
cent vs. 21.4 percent, NS) at both 30 days and at 6 months. Considering the small sam- 
ple size, these results must be interpreted cautiously. However shock patients are 
usually excluded from randomized trials and little information is available for this popula- 
tion. Primary stenting with abciximab in AMI complicated by cardiogenic shock appears 
to provide similar benefit as in the rest of the population of this trial. These results would 
need further confirmation in a specific trial. 
1126-17 Totally Occluded In-Stent Restenotic Lesions Treated 
With Intracoronary Radiation: Six-Month Clinical and 
Anglographic Follow-Up 
Andrew E. A!ani, Edouard Cheneau, Dong-Hun Cha, Rosanna Chart, Hongsheng Wu, 
Hamid Yazdi, Daniel Canos, Augusto D. Pichard, Lowell F. Satler, Kenneth M. Kent, 
Joseph Lindsay, Ron Waksman, Washington Hospital Center, Washington, Dist. of 
Columbia. 
Background: Conventional PTCA of totally occluded (TO) coronary arteries with in-stent 
restenosis (ISR) is associated with higher rates of restenosis and reocclusion. The pur- 
pose of this study was to evaluate the effectiveness of intracoronary radiation therapy 
(IRT) in patients (pts) with TO of ISR lesions. Methods: Out of 669 patients who were 
enrolled into the WRIST studies (Washington Radiation for In-Stant Restenosis Trial) 
treated with a 7 emitter (Ir-192) and had 6-month clinical follow-up, 82 pts (12%) pre- 
sented at entry with TO of the target lesion. Seventy-nine of these patients (94%) under- 
went successful intervention using balloon, laser angioplasty, or additional stents (39%) 
to obtain an adequate angiographic result (<30% diameter stenosis). Results: Angio- 
graphic and clinical outcomes comparing pts with TO versus non-occlusive lesions were 
similar except for higher rates of late total occlusion (LTO) in the TO group (Table). Con- 
clusions: Total occlusion of ISR lesions at entry in the WRIST studies is not infrequent 
and has a successful recanalization rate with conventional percutaneous coronary inter- 
vention. Intrecoronary 7 radiation therapy for totally occluded ISR is feasible, safe and 
associated with similar outcomes to non-occlusive ISR. 
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Total Occlusion Non-Total Occlusion P value 
(N=82) (N=587) 
Angiographic Binary Restenosis, % 31 
Death, % 4 
Q-wave MI, % 3 
TLR, % 20 
28 0.67 
3 0.70 
1 0.36 
20 0.95 
28 0.41 
5 0.03 
30 0.42 
TVR, % 24 
Late Total Occlusion, % 12 
MACE, % 25 
1126-18 Acute Coronary Syndrome Is a Common Clinical 
Presentation of In-Stent Restenosis 
Darren Waiters. Scott Harding, Craig Walsh, Phillip Wong, Eugene Pomerantsev, Ik- 
kyung Jang, Massachusetts General Hospital, Boston, Massachusetts. 
Background; Coronary stents have been the major advancement in percutaneous coro- 
nary intervention (PCt) in the last decade and are used in 60 - 80% of the patients. How- 
ever, in-stent restenosis continues to be a problem, occurring in 20 - 30% of cases. The 
clinical presentation of patients who develop restenosis following stenting has not been 
well characterized. In this study we compared the clinical presentation of in-stant rest- 
enosis with that of PCI without stenting. 
Methods; Of 742 patients who underwent PCI and had repeat catheterization between 
10/1/97 and 6/30/00, 262 consecutive patients with recurrent iechemia and restenosis 
were identified: 191 patients with stenting (Group A) and 71 without stenting (Group B). 
Patients who underwent interventions in bypass grafts and those who developed eady 
acute stent thrombosis were excluded from the study 
Results; Recurrent clinical ischemia occurred at e mean of 5.5 months for Group A and 
6.4 months for Group B (p=0.24). Rest aegina (Braunwald Class II and III) was more fre- 
quent in Group A compared to Group B (47 vs 23%, p<0.05). Acute coronary syndromes, 
the combination of rest angina and acute myocardial infarction, were also more frequent 
in Group A (67 vs 46%, p<0.05). Patients in Group A were more likely to have anglo- 
graphically visible thrombus compared with those in Group B (9 vs 0%, p<0.05). 
Conclusions: The acute coronary syndromes are a common clinical presentation of rest- 
enosis in patients undergoing repeat angiography and occur more frequently in patients 
with in-steet restenosis compared to those with balloon angioplasty restenosis. 
1126-19 One-Year Outcomes of Unprotected and Protected Left 
Main Stenting in the Current Era 
Michael P. Kellev, Bruce D. Klugherz, Sayed M. Hashemi, Nicolas F. Meneveau, Janet M. 
Johnston, William H. Matthai, Jr., Vidya S. Banks, Howard C. Herrmann, John W. 
Hirshfeld, Jr., Daniel M. Kolansky, Phillip A. Horwitz, Francois Schiele, Jean-Pierre L. 
Bassand, Robert L. Wilensky, University of Pennsylvania Health System, Philadelphia, 
Pennsylvania, Cardiology Section, Hopital Jean Minjoz, Besancon, France. 
Backoround: Although coronary artery bypass surgery is the accepted treatment for left 
main coronary artery (LMCA) disease, improved coronary interventional techniques may 
facilitate a percutaneous approach. Data regarding patient outcomes following left main 
stenting remain limited. 
Methods: We retrospectively reviewed outcomes among 135 consecutive patients who 
underwent protected (left coronary artery grafted) or unprotected LMCA stenting and for 
whom one-year follow-up was available. Death, myocardial infarction (MI), target-lesion 
revascularization (TLR), and the combined major adverse clinical event (MACE) rates 
were computed. Demographic and procedural variables were tested in univariate and 
multivariate prediction models. 
Results: Mean age was 68 _+ 10 years and mean ejection fraction 48 + 10%. Ninety-four 
patients (70%) underwent protected and 41 patients (30%) underwent unprotected 
LMCA steering. Cardiogenic shock was present in 6% of patients. Glycoprotein 2B/3A 
receptor antagonists were used in 56 patients (43%). Clinical follow-up was obtained in 
95% of patients. Survival at one year was 88% for all patients (protected 95% and unpro- 
tected 71%), TLR 21%, and MACE 34%. For the 8 patients with cardiogenic shock, one- 
year survival was 50%. In a multivariate analysis, independent predictors of mortality 
included unprotected LMCA stent (odds ratio [OR] 8.7, 2.2-34.6, p=0.002) and cardio- 
ganic shock (OR 6.0, 1.03-34.9, p=0.05). Congestive heart failure was a univariate pre- 
dictor of survival (OR 3.3, 1.1-9.6, p=0.03). No univadate predictors of TLR were 
identified. 
Conclusion: In the setting of protected LMCA disease, percutaneous intervention has 
an acceptable one-year survival. Survival is reduced following unprotected LMCA stent- 
ing in this selected population of poor surgical candidates. In contrast to previous out- 
comes analyses of patients undergoing coronary stenting, diabetes is not e predictor of 
left main TLR or MACE. Target-lesion revascularization for left main stents appears simi- 
lar to stenting of other large corenaPJ arteries. 
